Prognostic Implications of NOTCH1 and FBXW7 Mutations in Adults With T-Cell Acute Lymphoblastic Leukemia Treated on the MRC UKALLXII/ECOG E2993 Protocol
Authors:
- Marc R. MansourMMMarc R. Mansour
- Maria L. SulisMSMaria L. Sulis
- Veronique DukeVDVeronique Duke
- Letizia ForoniLFLetizia Foroni
- Sarah JenkinsonSJSarah Jenkinson
- Kenneth KooKKKenneth Koo
- Christopher G. AllenCAChristopher G. Allen
- Rosemary E. GaleRGRosemary E. Gale
- Georgina BuckGBGeorgina Buck
- Sue RichardsSRSue Richards
- Elisabeth PaiettaEPElisabeth Paietta
- Jacob M. RoweJRJacob M. Rowe
- 10 September 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (26) , 4352-4356
Abstract
Purpose: Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome. Their prognostic significance in adult T-ALL is unclear. We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol. Methods: NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome. Results: NOTCH1 and FBXW7 mutations were common (60% and 18%, respectively) and were not associated with age or WBC count. NOTCH1 heterodimerization domain mutations were associated with FBXW7 mutations (P = .02), and NOTCH1 proline, glutamic acid, serine, threonine (PEST) rich domain and FBXW7 mutations were mutually exclusive. There were an equal number of high- and standard-risk patients in the NOTCH1 and FBXW7 mutated (MUT) groups. Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6). Analysis by each marker individually was not significantly predictive of outcome (NOTCH1 MUT v WT, EFS 49% v 34%, P = .20; FBXW7 MUT v WT, EFS 53% v 41%, P.72). Conclusion: NOTCH1 and FBXW7 mutant-positive patients do not fare sufficiently well to warrant an individualized treatment approach in future studies.Keywords
This publication has 29 references indexed in Scilit:
- NOTCH1 extracellular juxtamembrane expansion mutations in T-ALLBlood, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitorsJournal of Experimental Medicine, 2007
- The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemiaJournal of Experimental Medicine, 2007
- Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemiaBlood, 2007
- Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancersNature, 2007
- NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growthProceedings of the National Academy of Sciences, 2006
- c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphomaGenes & Development, 2006
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004
- Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemiaThe Lancet, 2004